Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer.

YC Shen, PH Chiang, HL Luo, YC Chuang, Yi-Ting Chen, CH Kang, CC Hsu, WC Lee, YT Cheng

Research output: Contribution to journalJournal Article peer-review

5 Scopus citations

Abstract

To determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA) response, and adverse events. The study included 33 patients receiving ≤ 10 cycles of docetaxel and 40 patients receiving > 10 cycles. Patients receiving > 10 cycles were younger than those who received ≤ 10 cycles. There was no statistical significant difference in overall survival between the two groups (log-rank test, p = 0.75). Adverse effects were more common among patients receiving ≥ 10 cycles of treatment. A PSA flare-up was observed among six patients (8.2%); the median duration of the PSA surge was 3 weeks (range, 3-12 weeks). The overall survival rates in patients with PSA flare-up were comparable with the patients having PSA response. We concluded that at least four cycles of docetaxel should be administered in metastatic castration-resistant prostate cancer patients in order not to cease treatment prematurely from potentially beneficial chemotherapy. However, administering > 10 cycles does not result in any further improvement in survival and is associated with more adverse effects.
Original languageAmerican English
Pages (from-to)458-463
JournalThe Kaohsiung Journal of Medical Sciences
Volume32
Issue number9
DOIs
StatePublished - 2016

Fingerprint

Dive into the research topics of 'Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer.'. Together they form a unique fingerprint.

Cite this